

Care Pathway for the Management and Referral of Transvaginal Mesh Complications

Synthetic transvaginal mesh has been used to manage pelvic organ prolapse (POP) and stress urinary incontinence (SUI) in Australian women for over 15 years. In November 2017 the Therapeutic Goods Administration removed transvaginal mesh products where the sole use is the treatment of POP. Transvaginal mesh is a recommended treatment for SUI in women. Some women experience significant complications associated with transvaginal mesh following treatment for POP and SUI. This care pathway assists general practitioners to assess and manage women who may be experiencing transvaginal mesh complications.

